This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Morgan Stanley Keeps Their Buy Rating on CVS Health (CVS)

Tipranks - Tipranks - Tue Aug 11, 7:36AM CDT

Morgan Stanley analyst Erin Wright maintained a Buy rating on CVS Health today and set a price target of $111.00.

Claim 55% Off TipRanks

According to TipRanks, Wright is a 5-star analyst with an average return of 15.2% and a 64.19% success rate. Wright covers the Healthcare sector, focusing on stocks such as CVS Health, UnitedHealth, and Humana.

Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $113.75.

See Insiders’ Hot Stocks on TipRanks >>

Based on CVS Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $106.1 billion and a net profit of $3 billion. In comparison, last year the company earned a revenue of $98.92 billion and had a net profit of $1.02 billion

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVS in relation to earlier this year. Most recently, in May 2026, LARRY ROBBINS, a Director at CVS sold 3,372,000.00 shares for a total of $317,445,666.16.

Read More on CVS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).